F. Doyle William's most recent trade in ProKidney Corp - Ordinary Shares - Class A was a trade of 125,862 Director stock option (right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ProKidney Corp - Ordinary ... | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 125,862 | 125,862 | - | - | Director stock option (right to buy) | |
| Elanco Animal Health Inc | William F. Doyle | Director | 29 Nov 2024 | 18,169 | 94,499 (0%) | 0% | 0 | Common Stock | ||
| ProKidney Corp - Ordinary ... | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 62,558 | 62,558 | - | - | Director stock option (right to buy) | |
| Elanco Animal Health Inc | William F. Doyle | Director | 21 May 2024 | 15,000 | 76,330 (0%) | 0% | 17.0 | 254,700 | Common Stock | |
| Elanco Animal Health Inc | William F. Doyle | Director | 08 Mar 2024 | 15,000 | 61,330 (0%) | 0% | 16.3 | 244,500 | Common Stock | |
| Elanco Animal Health Inc | F. Doyle William | Director | 30 Nov 2023 | 20,374 | 46,330 (0%) | 0% | 0 | Common Stock | ||
| ProKidney Corp - Ordinary ... | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 48,128 | 48,128 | - | - | Director Stock Option (right to buy) | |
| Elanco Animal Health Inc | William F. Doyle | Director | 30 Nov 2022 | 18,649 | 25,956 (0%) | 0% | 0 | Common Stock | ||
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 69.66 per share. | 02 Aug 2022 | 837 | 551,176 (0%) | 0% | 69.7 | 58,305 | Ordinary Shares |
| ProKidney Corp - Ordinary ... | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 1,514,326 | 1,514,326 | - | - | Class B Ordinary Shares | |
| ProKidney Corp - Ordinary ... | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 1,514,326 | 1,514,326 | - | - | Common Units in ProKidney LP | |
| Minerva Neurosciences Inc | William F. Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 2,500 | 2,500 | - | - | Stock Option (right to buy) | |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 70.10 per share. | 08 Mar 2022 | 2,385 | 552,013 (0%) | 0% | 70.1 | 167,189 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 14,581 | 14,581 | - | - | Options to Buy Ordinary Shares | |
| Elanco Animal Health Inc | William F. Doyle | Director | 30 Nov 2021 | 7,307 | 7,307 (0%) | 0% | 0 | Common Stock | ||
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 149.38 per share. | 02 Aug 2021 | 995 | 554,398 (0%) | 0% | 149.4 | 148,631 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 197.00 per share. | 13 Apr 2021 | 24,338 | 610,251 (0%) | 0% | 197.0 | 4,794,659 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 197.83 per share. | 13 Apr 2021 | 13,612 | 596,639 (0%) | 0% | 197.8 | 2,692,876 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 198.98 per share. | 13 Apr 2021 | 10,563 | 586,076 (0%) | 0% | 199.0 | 2,101,794 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 196.07 per share. | 13 Apr 2021 | 8,814 | 634,589 (0%) | 0% | 196.1 | 1,728,187 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 207.80 per share. | 13 Apr 2021 | 4,500 | 561,314 (0%) | 0% | 207.8 | 935,118 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 202.16 per share. | 13 Apr 2021 | 4,388 | 573,225 (0%) | 0% | 202.2 | 887,069 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 199.71 per share. | 13 Apr 2021 | 4,338 | 581,738 (0%) | 0% | 199.7 | 866,355 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 201.55 per share. | 13 Apr 2021 | 4,125 | 577,613 (0%) | 0% | 201.5 | 831,377 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 203.25 per share. | 13 Apr 2021 | 2,555 | 570,670 (0%) | 0% | 203.3 | 519,311 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 209.34 per share. | 13 Apr 2021 | 2,200 | 559,114 (0%) | 0% | 209.3 | 460,555 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 193.57 per share. | 13 Apr 2021 | 2,090 | 645,003 (0%) | 0% | 193.6 | 404,563 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 204.28 per share. | 13 Apr 2021 | 1,972 | 568,698 (0%) | 0% | 204.3 | 402,834 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 192.52 per share. | 13 Apr 2021 | 1,900 | 647,093 (0%) | 0% | 192.5 | 365,796 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 205.43 per share. | 13 Apr 2021 | 1,600 | 567,098 (0%) | 0% | 205.4 | 328,690 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 194.94 per share. | 13 Apr 2021 | 1,600 | 643,403 (0%) | 0% | 194.9 | 311,904 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 213.35 per share. | 13 Apr 2021 | 1,500 | 556,493 (0%) | 0% | 213.3 | 320,021 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 191.26 per share. | 13 Apr 2021 | 1,400 | 648,993 (0%) | 0% | 191.3 | 267,768 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 206.35 per share. | 13 Apr 2021 | 1,284 | 565,814 (0%) | 0% | 206.4 | 264,956 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 211.28 per share. | 13 Apr 2021 | 600 | 557,993 (0%) | 0% | 211.3 | 126,766 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 216.69 per share. | 13 Apr 2021 | 600 | 555,393 (0%) | 0% | 216.7 | 130,016 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 210.18 per share. | 13 Apr 2021 | 521 | 558,593 (0%) | 0% | 210.2 | 109,504 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 214.67 per share. | 13 Apr 2021 | 500 | 555,993 (0%) | 0% | 214.7 | 107,333 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.25 per share. | 31 Mar 2021 | 9,259 | 658,321 (0%) | 0% | 125.3 | 1,159,690 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2021 | 9,259 | 0 | - | - | Restricted Stock Units | |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 134.12 per share. | 31 Mar 2021 | 7,928 | 650,393 (0%) | 0% | 134.1 | 1,063,303 | Ordinary Shares |
| NovoCure Ltd | William F. Doyle | Director, Executive Chairman | Sale of securities on an exchange or to another person at price $ 76.39 per share. | 31 Jul 2020 | 896 | 649,062 (0%) | 0% | 76.4 | 68,444 | Ordinary Shares |